Methylparaben and propylparaben are widely used as preservatives in consumer products, including cosmetics, personal care items, and pharmaceuticals. Concerns have been raised regarding their potential for systemic absorption and estrogenic activity, which may contribute to endocrine disruption. This review evaluates current evidence on dermal absorption, metabolism, and systemic distribution of methylparaben and propylparaben, emphasizing factors influencing their bioavailability. Additionally, the estrogenic potential of these compounds in experimental studies is examined, assessing receptor binding affinity and biological effects. Overall, while parabens exhibit weak estrogenic activity compared to endogenous hormones, repeated exposure and cumulative effects warrant further investigation. The toxicokinetic data combined with estrogenic activity assessments provide critical insight into the risk of endocrine disruption associated with paraben exposure. This assessment provides an understanding of methylparaben and propylparaben safety, supporting informed regulatory decisions and consumer awareness.
CaonTCostaACde OliveiraMA, et al. (2010) Evaluation of the transdermal permeation of different paraben combinations through a pig ear skin model. International Journal of Pharmaceutics391(1-2): 1–6.
2.
CatheyALNguyenVKColacinoJA, et al. (2023) Exploratory profiles of phenols, parabens, and per- and poly-fluoroalkyl substances among NHANES study participants in association with previous cancer diagnoses. Journal of Exposure Science and Environmental Epidemiology33(5): 687–698.
3.
ChangCJO'BrienKMKeilAP, et al. (2024) Use of personal care product mixtures and incident hormone-sensitive cancers in the sister study: a U.S.-Wide prospective cohort. Environment International183: 108298.
4.
CrossSERobertsMS (2000) The effect of occlusion on epidermal penetration of parabens from a commercial allergy test ointment, acetone and ethanol vehicles. Journal of Investigative Dermatology115(5): 914–918.
5.
El HusseinSMuretPBerardM, et al. (2007) Assessment of principal parabens used in cosmetics after their passage through human epidermis-dermis layers (ex-vivo study). Experimental Dermatology16(10): 830–836.
6.
FarooqHMhatrePAggarwalR, et al. (2024) A systematic review of association between use of hair products and benign and malignant gynecological conditions. European Journal of Obstetrics & Gynecology and Reproductive Biology295: 160–171.
7.
FranswayAFFranswayPJBelsitoDV, et al. (2019) Paraben toxicology. Dermatitis30(1): 32–45.
8.
GoldbergMChangCJOgunsinaK, et al. (2024) Personal care product use during puberty and incident breast cancer among black, hispanic/latina, and white women in a prospective US-Wide cohort. Environmental Health Perspectives132(2): 27001.
9.
GoldenRGandyJVollmerG (2005) A review of the endocrine activity of parabens and implications for potential risks to human health. Critical Reviews in Toxicology35(5): 435–458.
10.
GomezEPillonAFenetH, et al. (2005) Estrogenic activity of cosmetic components in reporter cell lines: parabens, UV screens, and musks. Journal of Toxicology and Environmental Health, Part A68(4): 239–251.
11.
HagerEChenJZhaoL (2022) Minireview: Parabens exposure and breast cancer. International Journal of Environmental Research and Public Health19(3): 1–15.
12.
HajizadehYKiani FeizabadiGEbrahimpourK, et al. (2020) Urinary paraben concentrations and their implications for human exposure in Iranian pregnant women. Environmental Science and Pollution Research International27(13): 14723–14734.
13.
HernandezAMSmithSJVahoraMS, et al. (2025) Systematic review of the epidemiology of hair relaxer use and hormone-sensitive reproductive outcomes among black adult women in the United States. Journal of Applied Toxicology45(8): 1394–1416.
14.
IshiwatariSSuzukiTHitomiT, et al. (2007) Effects of methyl paraben on skin keratinocytes. Journal of Applied Toxicology27(1): 1–9.
15.
JewellCPrusakiewiczJJAckermannC, et al. (2007) Hydrolysis of a series of parabens by skin microsomes and cytosol from human and minipigs and in whole skin in short-term culture. Toxicology and Applied Pharmacology225(2): 221–228.
16.
KurmanRJShih IeM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. The American Journal of Surgical Pathology34(3): 433–443.
17.
LeminiCJaimezRAvilaME, et al. (2003) In vivo and in vitro estrogen bioactivities of alkyl parabens. Toxicology and Industrial Health19(2-6): 69–79.
18.
LeminiCHernandezAJaimezR, et al. (2004) Morpometric analysis of mice uteri treated with the preservatives methyl, ethyl, propyl, and butylparaben. Toxicology and Industrial Health20: 123–132.
19.
LobemeierCTschoetschelCWestieS, et al. (1996) Hydrolysis of parabens by extracts from differing layers of human skin. Journal of Biological Chemistry377: 647–651.
NowakKRatajczak-WronaWGorskaM, et al. (2018) Parabens and their effects on the endocrine system. Molecular and Cellular Endocrinology474: 238–251.
22.
PazourekovaSHojerovaJKlimovaZ, et al. (2013) Dermal absorption and hydrolysis of methylparaben in different vehicles through intact and damaged skin: using a pig-ear model in vitro. Food and Chemical Toxicology59: 754–765.
23.
PedersenSMarraFNicoliS, et al. (2007) In vitro skin permeation and retention of parabens from cosmetic formulations. International Journal of Cosmetic Science29(5): 361–367.
24.
PugazhendhiDPopeGSDarbrePD (2005) Oestrogenic activity of p-hydroxybenzoic acid (common metabolite of paraben esters) and methylparaben in human breast cancer cell lines. Journal of Applied Toxicology25(4): 301–309.
25.
RoutledgeEJParkerJOdumJ, et al. (1998) Some alkyl hydroxyl benzoate preservatives (parabens) are estrogenic. Toxicology and Applied Pharmacology153: 12–19.
26.
SarinkDFrankeAAWhiteKK, et al. (2021) BPA, parabens, and phthalates in relation to endometrial cancer risk: a case-control study nested in the multiethnic cohort. Environmental Health Perspectives129(5): 57702.
27.
SCCS (2021) Opinion on Propylparaben (PP). SCCS/1623/20. Brussells, Belgium: Scientific Committee on Consumer Safety.
28.
SCCS (2024) Opinion on methylparaben(CAS No. 99-76-3, EC No. 202-785-7). SCCS/1652/23, February 2024. Brussells, Belgium: Scientific Committee on Consumer Safety.
29.
Sd H, S AP and Y PC (2025) A review on synthesis of paraben and applications of preservatives. International Journal of Indigenous Herbs and Drugs10(1): 1–5.
30.
ShermanME (2000) Theories of endometrial carcinogenesis: a multidisciplinary approach. Modern Pathology13(3): 295–308.
31.
ShinMYChoiJWLeeS, et al. (2023) Pharmacokinetics of transdermal methyl-ethyl-and propylparaben in humans following single dermal administration. Chemosphere310: 136689.
32.
SoniMGTaylorSLGreenbergNA, et al. (2002) Evaluation of the health aspects of methyl paraben: a review of the published literature. Food and Chemical Toxicology40(10): 1335–1373.
33.
SoniMGCarabinIGBurdockGA (2005) Safety assessment of esters of p-hydroxybenzoic acid (parabens). Food and Chemical Toxicology43(7): 985–1015.
34.
SunLYuTGuoJ, et al. (2016) The estrogenicity of methylparaben and ethylparaben at doses close to the acceptable daily intake in immature Sprague-Dawley rats. Scientific Reports6: 25173.
35.
XiongYLiZXiongX, et al. (2025) Associations between phenol and paraben exposure and the risk of developing breast cancer in adult women: a cross-sectional study. Scientific Reports15(1): 4038.
